regulator of G protein signaling 17 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored RGS17P1 profile across patient tissues and cancer cell-line models. RGS17P1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RGS17P1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, RGS17P1 RNA expression shows 16,657 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, BLCA, and DLBC as cancer lineages where RGS17P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS17P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS17P1 survival associations across molecular data types. RGS17P1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS17P1 RNA expression–survival associations across cancer types. High RGS17P1 expression shows unfavorable associations in THCA, CESC and COAD, but favorable associations in SKCM, LUAD and LAML. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for RGS17P1 RNA expression.
This table summarizes RGS17P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RGS17P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS17P1 shows lower tumor expression in THCA and higher tumor expression in BLCA, STAD, BRCA, HNSC and KIRC. The BLCA box plot shows higher RGS17P1 RNA expression in tumor versus normal tissue (log2 FC = +0.894, t-test p = .004).
This table shows molecular features associated with RGS17P1 in patient tissues and cancer cell lines. In patient samples, RGS17P1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
